logo

MNMD

Mind Medicine·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

MNMD fundamentals

Mind Medicine (MNMD) released its earnings on Nov 6, 2025: revenue was 0 (YoY 0.00%), beat estimates; EPS was -0.78 (YoY -188.89%), missed estimates.
Revenue / YoY
0
0.00%
EPS / YoY
-0.78
-188.89%
Report date
Nov 6, 2025
MNMD Earnings Call Summary for Q3,2025
  • $259M Fundraise Strengthens Pipeline: Accelerates MM120 NDA prep and MM402 development.
  • 2026 Pivotal Readouts: Three phase 3 studies deliver GAD and MDD data, with Emerge advancing to mid-2026.
  • ASD Breakthrough Potential: MM402 phase 2A to test chronic administration for social communication in ASD.
  • Financial Resilience: $242.8M net proceeds extend cash runway to 2028, supporting aggressive execution.
EPS
Revenue

Revenue & Expenses

Key Indicators

Mind Medicine (MNMD) key financial stats and ratios, covering profitability, financial health, and leverage.
Mind Medicine (MNMD)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Mind Medicine (MNMD)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Mind Medicine (MNMD)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Mind Medicine (MNMD) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Mind Medicine (MNMD) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield